05:45 PM EDT, 05/27/2025 (MT Newswires) -- Teva Pharmaceutical Industries ( TEVA ) said late Tuesday its investigational anti-IL-15 antibody to treat celiac disease was granted fast track designation by the US Food and Drug Administration.
The monoclonal antibody candidate's efficacy and safety profile are currently being assessed in a phase 2a trial, according to a statement.
Shares were up 1.6% in after-hours trading.